Video

Dr. Ai on the FDA Approval of Mogamulizumab in CTCL

Author(s):

Wei Z. Ai, MD

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Related Content
Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

Brandon Blue, MD
October 1st 2021

Dr. Blue on the Utility of Carfilzomib in Relapsed/Refractory Multiple Myeloma

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma
July 29th 2020

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma
June 11th 2020

Dr. Jacobson on the Benefit of Axi-Cel in Relapsed/Refractory Follicular Lymphoma

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer
June 2nd 2020

Dr. Katz on Determining Low-Risk Disease in Prostate Cancer